El-Deiry W - Search Results

1

Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation.

Hsiehchen D, Elliott A, Xiu J, Seeber A, El-Deiry W, Antonarakis ES, Graff SL, Hall MJ, Borghaei H, Hoon DSB, Liu SV, Ma PC, McKay RR, Wise-Draper T, Marshall J, Sledge GW, Spetzler D, Zhu H. Hsiehchen D, et al. Among authors: el deiry w. Cancer Cell. 2024 Dec 9;42(12):1985-1987. doi: 10.1016/j.ccell.2024.10.017. Epub 2024 Nov 21. Cancer Cell. 2024. PMID: 39577419

2

Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes.

Zorko NA, Makovec A, Elliott A, Kellen S, Lozada JR, Arafa AT, Felices M, Shackelford M, Barata P, Zakharia Y, Narayan V, Stein MN, Zarrabi KK, Patniak A, Bilen MA, Radovich M, Sledge G, El-Deiry WS, Heath EI, Hoon DSB, Nabhan C, Miller JS, Hwang JH, Antonarakis ES. Zorko NA, et al. Prostate Cancer Prostatic Dis. 2024 Feb 28:10.1038/s41391-024-00797-0. doi: 10.1038/s41391-024-00797-0. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38418892

3

GSK-3 inhibitor elraglusib enhances tumor-infiltrating immune cell activation in tumor biopsies and synergizes with anti-PD-L1 in a murine model of colorectal cancer.

Huntington KE, Louie AD, Srinivasan PR, Schorl C, Lu S, Silverberg D, Newhouse D, Wu Z, Zhou L, Borden BA, Giles FJ, Dooner M, Carneiro BA, El-Deiry WS. Huntington KE, et al. bioRxiv [Preprint]. 2023 Feb 7:2023.02.07.527499. doi: 10.1101/2023.02.07.527499. bioRxiv. 2023. Update in: Int J Mol Sci. 2023 Jun 29;24(13):10870. doi: 10.3390/ijms241310870. PMID: 36798357 Free PMC article. Updated. Preprint.

4

Novel combination of imipridones and histone deacetylase inhibitors demonstrate cytotoxic effect through integrated stress response in pediatric solid tumors.

Chang WI, Honeyman JN, Zhang J, Lin C, Sharma A, Zhou L, Oliveira J, Tapinos N, Lulla RR, Prabhu VV, El-Deiry WS. Chang WI, et al. Am J Cancer Res. 2023 Dec 15;13(12):6241-6255. eCollection 2023. Am J Cancer Res. 2023. PMID: 38187038 Free PMC article.

5

ONC201/TIC10 plus TLY012 anti-cancer effects via apoptosis inhibitor downregulation, stimulation of integrated stress response and death receptor DR5 in gastric adenocarcinoma.

Parker CS, Zhou L, Prabhu VV, Lee S, Miner TJ, Ross EA, El-Deiry WS. Parker CS, et al. Am J Cancer Res. 2023 Dec 15;13(12):6290-6312. eCollection 2023. Am J Cancer Res. 2023. PMID: 38187068 Free PMC article.

6

Dopamine pre-treatment impairs the anti-cancer effect of integrated stress response- and TRAIL pathway-inducing ONC201, ONC206 and ONC212 imipridones in pancreatic, colorectal cancer but not DMG cells.

Zhang Y, Tapinos N, Lulla R, El-Deiry WS. Zhang Y, et al. Am J Cancer Res. 2024 May 15;14(5):2453-2464. doi: 10.62347/ZOTV8006. eCollection 2024. Am J Cancer Res. 2024. PMID: 38859853 Free PMC article.

7

Synergistic anti-tumor activity, reduced pERK, and immuno-stimulatory cytokine profiles with 5-FU or ONC212 plus KRAS G12D inhibitor MRTX1133 in CRC and pancreatic cancer cells independent of G12D mutation.

Tajiknia V, Pinho-Schwermann M, Srinivasan PR, Hernandez Borrero L, Zhang L, Huntington KE, El-Deiry WS. Tajiknia V, et al. Among authors: el deiry ws. Am J Cancer Res. 2024 Sep 15;14(9):4523-4536. doi: 10.62347/DVXL1377. eCollection 2024. Am J Cancer Res. 2024. PMID: 39417197 Free PMC article.

8

Synergistic combination therapy with ONC201 or ONC206, and enzalutamide or darolutamide in preclinical studies of castration-resistant prostate cancer.

Wu LJ, Pinho-Schwermann M, Zhou L, Zhang L, Huntington KE, Malpass R, Seyhan AA, Carneiro BA, El-Deiry WS. Wu LJ, et al. Among authors: el deiry ws. Am J Cancer Res. 2024 Dec 25;14(12):6012-6036. doi: 10.62347/VJMW4904. eCollection 2024. Am J Cancer Res. 2024. PMID: 39803644 Free PMC article.

9

Cancer cell seeding density as a mechanism of chemotherapy resistance: a novel cancer cell density index based on IC50-Seeding Density Slope (ISDS) to assess chemosensitivity.

Punyamurtula U, Brown TW, Zhang S, George A, El-Deiry WS. Punyamurtula U, et al. Am J Cancer Res. 2023 Dec 15;13(12):5914-5933. eCollection 2023. Am J Cancer Res. 2023. PMID: 38187067 Free PMC article.

10

Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers and overcomes cancer stemness, trifluridine-induced angiogenesis, ERK1/2 and STAT3 signaling regardless of KRAS or BRAF mutational status.

Zhang J, Zhou L, Zhao S, El-Deiry WS. Zhang J, et al. Oncotarget. 2024 Jul 2;15:424-438. doi: 10.18632/oncotarget.28602. Oncotarget. 2024. PMID: 38953895 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

508 results

Search Page

Filters